Log In
BCIQ
Print this Print this
 

ALTU-237

  Manage Alerts
Collapse Summary General Information
Company Ajinomoto Co. Inc.
DescriptionCrystalline formulation of an oxalate-degrading enzyme
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I
Standard IndicationHyperoxaluria
Indication DetailsTreat hyperoxaluria
Regulatory Designation
PartnerAllena Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/28/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today